Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation

NCT ID: NCT05039359

Last Updated: 2023-10-30

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 54 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-04-26
• Study Completion Date: 2023-05-22

Brief Summary

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical study designed to evaluate the efficacy and safety of FlecIH-103 (flecainide acetate inhalation solution) compared with placebo in patients with recent-onset, symptomatic newly diagnosed or paroxysmal AF. Approximately 400 patients are expected to be enrolled in this study. Patients will be randomized 3:1 to receive FlecIH-103 at a total dose of up to 120 mg estimated total lung dose (eTLD) (n=300) or placebo inhalation solution (n=100). Randomization will be stratified by geographic region (US and ex-US) and duration of symptoms of the current AF episode (≥1 hour to ≤24 hours and >24 hours to ≤48 hours).

Detailed Description

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical study designed to evaluate the efficacy and safety of FlecIH-103 (flecainide acetate inhalation solution) compared with placebo in patients with recent-onset, symptomatic newly diagnosed or paroxysmal AF. Approximately 400 patients are expected to be enrolled in this study. The study will consist of the following periods: Screening, Observation, and Follow-up.

The Screening Period comprises the time from the patient signing informed consent to the time of randomization. Screening begins at least 45 minutes prior to dosing and may be extended as needed due to site logistics. During screening, the patient will be evaluated for study eligibility, have a standard triplicate 12-lead ECG to confirm the diagnosis of AF, have a single-lead patch electrode applied for continuous ECG (cECG) recording, undergo a targeted physical examination (including cardiovascular and respiratory systems), have blood drawn for laboratory assessments and a predose pharmacokinetic (PK) sample, have their AF-related symptoms assessed, have vital signs assessed periodically, and be monitored via telemetry to ensure they remain predominantly in AF prior to dosing (ie, no period of SR ≥1 minute in duration or any abnormal rhythm other than AF). After confirmation that the patient meets all applicable eligibility criteria, randomization will take place using a central randomization system. The patient is considered enrolled at the time of randomization.

The Observation Period comprises the time from randomization through 90 minutes after initiation of dosing. After randomization and just prior to the start of dosing (T0), the patient's AF will again be confirmed by a standard triplicate 12-lead ECG; patients who are not in AF at this time must be withdrawn. The patient will inhale the study drug until conversion of AF to SR occurs for ≥1 minute or the complete dose is administered, whichever occurs first. The complete dose of study drug comprises 2 separate 3.5-minute inhalations separated by a 1-minute break. Telemetric recording of ECG and cECG monitoring will continue and vital signs will be monitored periodically. A PK sample will be collected 2 minutes after completion of dosing followed by another standard triplicate ECG collected 5 minutes after completion of dosing. Finally, AF-related symptoms will be checked and a final PK sample will be collected at 90 minutes after initiation of dosing. Wherever a time point requires collection of ECG and/or vital signs in addition to a PK sample, the PK sample is collected last.

If the patient's AF converts to SR (sustained for ≥1 minute) as observed on telemetry during the Observation Period, vital signs and a standard triplicate 12-lead ECG will be recorded immediately following the time of conversion. The Investigator may not offer the patient another rhythm control therapy to cardiovert their AF to SR until after 90 minutes after initiation of dosing. At the end of the Observation Period (ie, 90 minutes after initiation of dosing), the cECG patch will be removed and a standard triplicate 12 lead ECG will be recorded. If the patient's AF converts to SR (sustained for ≥1 minute) after the Observation Period but prior to discharge (eg, due to ECV or other PCV), a standard triplicate 12-lead ECG will be recorded at the time of conversion.

The patient may be discharged per the Investigator's discretion any time after completion of the 90-minute time point assessments. If patient discharge occurs >1 hour after completion of the last 90-minute time point assessment, all 90-minute time point assessments must be repeated just prior to discharge, excluding the PK sample.

The Follow-Up Period consists of 2 follow-up telephone contacts: one at 24 (+12) hours after initiation of dosing, and one at 96 (±24) hours after initiation of dosing. The patient will also be given contact information and be instructed to contact the clinic in the event that any AF-related symptoms occur before these scheduled contact times. Follow-up contacts may also be performed by video call or in-person if the patient is at the clinic. During each follow-up contact, the patient will be queried for concomitant medications and procedures, AEs, AF-related symptoms, and AF-related interventions. End of study coincides with the 96-hour follow-up contact.

An independent Data Monitoring Committee (DMC) will monitor safety throughout the study. An independent Clinical Events Committee (CEC) will review blinded data to adjudicate the primary and several secondary efficacy endpoints and to adjudicate CV events of special interest (ie, hypotension, ventricular tachycardia, bradycardia, sinus pause, atrial flutter with 1:1 conduction, and other arrhythmias).

Conditions

Paroxysmal Atrial Fibrillation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

FlecIH-103 (flecainide acetate inhalation solution)

Up to two 3.5-minute inhalations separated by a 1-minute break, for a total duration of up to 8 minutes on Day 1. Dosing will continue until conversion of AF to SR is observed for ≥1 minute or the full dose (120 mg eTLD) is administered, whichever occurs first.

Group Type: ACTIVE_COMPARATOR

FlecIH-103

Intervention Type: DRUG

flecainide acetate inhalation solution

Vehicle-matched inhalation solution (placebo)

Up to two 3.5-minute inhalations separated by a 1-minute break, for a total duration of up to 8 minutes on Day 1.

Group Type: PLACEBO_COMPARATOR

FlecIH-103

Intervention Type: DRUG

flecainide acetate inhalation solution

Interventions

FlecIH-103

flecainide acetate inhalation solution

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. ≥18 and ≤85 years of age

2. Recent onset of symptomatic newly diagnosed or paroxysmal AF

1. Recent onset is defined as a symptom duration ≥1 and ≤48 hours at time of dosing

2. Newly diagnosed AF is AF that has not been diagnosed previously, independent of its duration

3. Paroxysmal AF is defined as recurrent AF in a patient whose previous AF episode(s) self-terminated (ie, without treatment) or terminated with intervention ≤7 days of onset.

4. A symptomatic recent-onset AF episode post cardiac ablation for paroxysmal AF would be considered eligible

Exclusion Criteria

1. History of non self-terminating AF/AFL as defined by

1. One or more failed attempts to restore SR with pharmacological therapy

2. ECV procedure for an AF episode ≤1 year prior to screening. Exception: One (1) prior ECV is allowed if no option for pharmacological conversion was previously available

3. More than 3 ECV procedures in ≤5 years prior to screening

2. Current diagnosis of persistent AF

1. Persistent AF defined as AF that is continuously sustained >7 days, including episodes terminated by cardioversion (drugs or electrical cardioversion) after >7 days. Patients with persistent AF do not have self-terminating AF episodes

2. Patients who have undergone an ablation procedure for persistent AF are not eligible

3. One or more episodes of AFL ≤6 months prior to randomization

a. Exception: a patient who has received ablation for AFL ≤3 months prior to screening with no recurrence of AFL prior to randomization is considered eligible Vital signs

4. Hemodynamic or cardiac instability during AF, defined as any of the following:

1. Systolic blood pressure <100 or ≥160 mmHg

2. Diastolic blood pressure ≥95 mmHg

3. Ventricular heart rate <80 or >160 bpm

5. Respiratory rate >22 breaths per minute Relevant structural heart disease

6. History of decompensated heart failure (HF)

7. Evidence of significant HF defined as any of the following:

a. Hospitalization in the last 12 months for HF or suspected HF event b. Most recent assessment of left ventricular ejection fraction (LVEF) <45% i. For patients in the United States, a standard diagnostic echocardiogram assessed ≤180 days prior to screening is required to ascertain eligibility. If none is available, the patient must undergo a standard diagnostic echocardiogram or a diagnostic echocardiogram using a portable ultrasound device (handheld echocardiogram [HHE]) during screening to confirm eligibility c. New York Heart Association (NYHA) Class II-IV symptoms d. Medication history suggestive of HF per the Investigator's discretion

8. Signs or symptoms of ongoing myocardial ischemia, including any of the following:

1. Significant ST segment elevation or depression (ie, ≥2 mm) on a standard 12-lead ECG

2. Echocardiogram findings (eg, wall motion abnormalities) suggestive of acute myocardial infarction (MI)

3. Angina pectoris, atypical angina pectoris, or receiving antianginal medication for ischemia

9. History of MI ≤3 months of screening

10. History of uncorrected moderate or severe aortic or mitral valvular stenosis, in the opinion of the Investigator

a. If an echocardiogram is performed at screening, moderate or severe valve disease observed during the examination is considered exclusionary

11. History of LV hypertrophy with LV thickness >12 mm as observed in the most recent assessment, ie, an echocardiogram Other CV conditions

12. Stroke (including transient ischemic attack) ≤3 months prior to randomization

13. History of any of the following cardiac abnormalities:

1. Long QT syndrome

2. Conduction system disease (eg, PR interval >200 ms, second- or third degree heart block, bundle branch block)

3. Brugada syndrome

4. Torsade de pointes

5. Diagnosed with sinus node dysfunction (eg, sick sinus syndrome) or any of the following:

i. History of unexplained or cardiovascular syncope ii. Bradycardia suggestive of sinus node dysfunction iii. Prior electrical or pharmacological cardioversion associated with sinus or ventricular pause >3 seconds or ventricular heart rate <45 bpm at time of conversion

14. Any of the following ECG-related features at screening:

1. QT interval corrected for heart rate using the Fridericia formula (QTcF) >480 msec

2. Wide QRS complex (ie, duration ≥120 msec) or history of documented wide QRS complex tachycardia (ie, wide QRS complex with ventricular heart rate >100 bpm)

3. Presence of ventricular tachycardia (VT). Site telemetry should be equipped with an alarm system for VT and PVCs or be continuously visually observed prior to dosing

15. Presence of a pacemaker

16. Cardiac surgery for any of the exclusionary conditions (eg, valvular disease, hypertrophy, coronary artery disease) ≤6 months prior to randomization Prior and concomitant non-CV conditions

17. Known severe renal impairment or patient receiving dialysis

18. Known abnormal liver function, including hepatic disease or biochemical evidence of significant liver derangement

19. Uncorrected hypokalemia

1. Hypokalemia is defined as serum potassium below the normal range according to the local laboratory reference ranges at screening

2. If serum potassium is below the normal range at screening, therapeutic correction (eg, potassium supplementation) is required

20. Uncorrected hypomagnesemia

1. Hypomagnesemia is defined as serum magnesium below the normal range according to the local laboratory reference ranges at screening

2. If serum magnesium result is below the normal range at screening, therapeutic correction (eg, magnesium supplementation) is required

21. Chronic obstructive pulmonary disease or other established pulmonary disease in need of inhalation medication

a. Exception: patients with intermittent mild asthma who are not experiencing active symptoms at screening, and whose asthma is well controlled with as-needed administration of a bronchodilator ≤2 days/week, and who has not experienced ≥2 exacerbations requiring oral systemic corticosteroids ≤1 year prior to screening

22. History of bronchospasm (eg, hyperreactive airways to inhalants) or difficulty inhaling medications

23. Previous or current hospitalization for COVID-19, or any secondary cardiomyopathy from COVID-19 Prior and concomitant medications and procedures

24. Treatment with Class I or III AADs ≤7 days prior to randomization

25. Treatment with amiodarone ≤12 weeks prior to randomization

26. Known hypersensitivity to flecainide acetate, any active metabolites of flecainide acetate, or any excipients in FlecIH-103

27. Any condition or circumstance which in the opinion of the Investigator may make the patient unsuitable for the study, such as:

1. High risk for stroke based on the screening coagulation panel or medical history per Investigator's discretion (eg, CHA2DS2-VASc score)

2. Congenital heart disease

3. AF that is secondary to electrolyte imbalance, thyroid disease, or other reversible or non-cardiovascular cause

4. A serious or life-threatening medical condition

5. An acute infection

28. Known drug or alcohol dependence ≤12 months prior to screening as judged by the Investigator

29. A body mass index ≥35 kg/m2

30. Legally incompetent to provide informed consent

31. Previous treatment with any other investigational drug ≤30 days from screening or 5 half-lives of the drug, whichever is longer

32. Female of childbearing potential defined as any of the following:

1. Not surgically sterile or postmenopausal (Appendix 1)

2. A negative pregnancy test is unavailable at screening

3. Pregnant or breastfeeding at screening

33. Males whose sexual partners are women of childbearing potential (WOCBP) must use at least one highly effective method of contraception during the study unless permenantly sterile by bilateral orchiectomy.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

InCarda Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Luiz Belardinelli, MD

Role: STUDY_DIRECTOR

InCarda Therapeutics, Inc.

Locations

UC Davis Medical Center

Davis, California, United States

Memorial Care

Long Beach, California, United States

Bridgeport Hospital

Bridgeport, Connecticut, United States

Orlando Health Heart and Vascular Institute and Orlando Regional medical Center

Orlando, Florida, United States

Tampa General Hospital; Center of Research Excellence

Tampa, Florida, United States

IU Health Ball Memorial Hospital

Muncie, Indiana, United States

Reid Physician Associates

Richmond, Indiana, United States

North Kansas City Hospital

Kansas City, Kansas, United States

University of Kansas Medical Center Research Institute

Kansas City, Kansas, United States

Saint Michaels Medical Center

Newark, New Jersey, United States

The Valley Hospital, Inc

Ridgewood, New Jersey, United States

Mount Sinal Hospital

New York, New York, United States

Weill Cornell Medical Center

New York, New York, United States

University of Cincinnati College of Medicine

Cincinnati, Ohio, United States

The MetroHealth System

Cleveland, Ohio, United States

Cleveland Clinic Emergency Department

Cleveland, Ohio, United States

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Reading Hospital

Reading, Pennsylvania, United States

EDUMED s.r.o.

Náchod, , Czechia

Nemocnice Slany

Slaný, , Czechia

DPC Hospital Egyesitett Szent Istvan es Szent Laszlo Korhaz

Budapest, , Hungary

University of PACs

Pécs, , Hungary

Deventer Ziekenhuis

Deventer, , Netherlands

Ziekenhuis Gelderse Vallei

Ede, , Netherlands

Admiraal de Ruyter Ziekenhuis

Goes, , Netherlands

Universitair Medisch Centrum Groningen (UMCG)

Groningen, , Netherlands

Spaarne Gasthuis

Haarlem, , Netherlands

Medisch Centrum Leeuwarden

Leeuwarden, , Netherlands

Diakonessenhuis

Utrecht, , Netherlands

Maxima Medisch Centrum

Veldhoven, , Netherlands

Mazowiecki Szpital Specjalistyczny w Ostrolece

Ostrołęka, , Poland

Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu

Torun, , Poland

Hospital General Universitario de Alicante

Alicante, , Spain

Hospital Universitari Vall d'Hebron

Barcelona, , Spain

Hospital Ramon y Cajal

Madrid, , Spain

Fundacion Jimenez Diaz

Madrid, , Spain

La Paz Univerisity Hospital

Madrid, , Spain

Hospital Universitario Puera de Hierro

Madrid, , Spain

Fundacion Hospital Son Liatzer

Palma de Mallorca, , Spain

Hospital Santiago De Compostela

Santiago de Compostela, , Spain

Countries

United States; Czechia; Hungary; Netherlands; Poland; Spain

References

Rienstra M, Woite-Silva AC, Kuijper A, Eijsbouts S, Kraaier K, Janota T, Van Ofwegen C, Tuininga Y, Badings E, Merino JL, Ruskin JN, Camm AJ, Kowey PR, Dufton C, Maupas J, Parsell D, Belardinelli L. Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial. Europace. 2025 Mar 28;27(4):euaf064. doi: 10.1093/europace/euaf064.

Reference Type: DERIVED

PMID: 40132102 (View on PubMed)

Other Identifiers

FLE-007

Identifier Type: -

Identifier Source: org_study_id